| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:FLT3-IN-10
CAS:2088735-51-5
Purity:大于98% Package:1g,5g,10g,25g根据客户需要分装 Remarks:Not For Human Use, Lab Use Only.
|
| Company Name: |
Wuhan chuang he chemical co. LTD
|
| Tel: |
15907120073 |
| Email: |
1261789306@qq.com |
| Products Intro: |
Product Name:FLT3-IN-10
CAS:2088735-51-5
Purity:98 Package:1g
|
| Company Name: |
Hefei fuya biotechnology co. LTD
|
| Tel: |
18096409024 |
| Email: |
sales02@foreversyn.com |
| Products Intro: |
Product Name:FLT3-IN-10
CAS:2088735-51-5
Purity:95% HPLC Package:100MG;500MG
|
|
| | 2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl- Basic information |
| | 2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl- Chemical Properties |
| Boiling point | 401.3±37.0 °C(Predicted) | | density | 1.265±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 3.53±0.10(Predicted) | | form | Solid | | color | Light yellow to light brown |
| | 2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl- Usage And Synthesis |
| Biological Activity | FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 has the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML)[1]. | | References | [1]. Kim HJ, et al. Discovery of Oxazol-2-amine Derivatives as Potent Novel FLT3 Inhibitors. Molecules. 2020;25(21):5154. |
| | 2-Oxazolamine, 5-(4-fluorophenyl)-N-phenyl- Preparation Products And Raw materials |
|